Pub. Date : 2021 Oct
PMID : 34795944
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer. | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 2 | Patients with EGFR G873R mutation had a significantly favorable prognosis of docetaxel (P=0.032), and for patients treated with docetaxel, EGFR G873R mutation was significantly correlated with better 5-year disease-free survival (DFS; P=0.026) and overall survival (OS; P=0.026). | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 3 | Patients with EGFR G873R mutation had a significantly favorable prognosis of docetaxel (P=0.032), and for patients treated with docetaxel, EGFR G873R mutation was significantly correlated with better 5-year disease-free survival (DFS; P=0.026) and overall survival (OS; P=0.026). | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 4 | Patients with EGFR G873R mutation had a significantly favorable prognosis of docetaxel (P=0.032), and for patients treated with docetaxel, EGFR G873R mutation was significantly correlated with better 5-year disease-free survival (DFS; P=0.026) and overall survival (OS; P=0.026). | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 5 | Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 6 | Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 7 | Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. | Docetaxel | epidermal growth factor receptor | Homo sapiens |
| 8 | Conclusions: EGFR G873R mutation was remarkably correlated with the prognosis of docetaxel in NSCLC, which indicates that EGFR G873R may be employed as a promising biomarker to identify individuals with better prognosis of docetaxel and as an antitumor target for NSCLC treatment. | Docetaxel | epidermal growth factor receptor | Homo sapiens |